Mereo BioPharma
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 33
- Market Cap
- $738.4M
- Introduction
Mereo BioPharma Group Plc is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that aim to improve outcomes for oncology and rare diseases. Its portfolio include Etigilimab (MPH-313), Alvelestat (MPH-966), Setrusumab (BPS-804), Navicixizumab (OMP-305B83), Acumapimod (BCT-197), and Leflutrozole (BGS-649). The company was founded by Denise Vera Scots-Knight, Charles Edward Sermon, Alastair Graham MacKinnon, and John P. Richard in March 10, 2015 and is headquartered in London, the United Kingdom.
Clinical Trials
12
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (12 trials with phase data)• Click on a phase to view related trials
A Study of Etigilimab and Nivolumab in Participants With Locally Advanced or Metastatic Tumors
- Conditions
- Solid Tumor, AdultMetastatic Solid TumorAdvanced Solid Tumor
- Interventions
- First Posted Date
- 2021-02-18
- Last Posted Date
- 2025-03-17
- Lead Sponsor
- Mereo BioPharma
- Target Recruit Count
- 76
- Registration Number
- NCT04761198
- Locations
- 🇺🇸
Mereo Investigator Site, Fairfax, Virginia, United States
🇬🇧Royal Marsden, London, United Kingdom
🇬🇧Sarah Cannon UK, London, United Kingdom
A 12-week Study Treating Participants Who Have alpha1-antitrypsin-related COPD With Alvelestat (MPH966) or Placebo.
- Conditions
- EmphysemaCOPDAlpha 1-Antitrypsin Deficiency
- Interventions
- First Posted Date
- 2018-08-17
- Last Posted Date
- 2022-04-14
- Lead Sponsor
- Mereo BioPharma
- Target Recruit Count
- 99
- Registration Number
- NCT03636347
- Locations
- 🇺🇸
University of Alabama, Birmingham (UAB), Birmingham, Alabama, United States
🇺🇸UCLA Medical Center, Los Angeles, California, United States
🇺🇸UC Davis Medical Centre, Sacramento, California, United States
The Effect of Itraconazole on BCT197 Exposure in Healthy Male Participants
- First Posted Date
- 2018-04-13
- Last Posted Date
- 2018-05-18
- Lead Sponsor
- Mereo BioPharma
- Target Recruit Count
- 16
- Registration Number
- NCT03498170
- Locations
- 🇺🇸
inVentiv Health Clinical Research Services LLC, Miami, Florida, United States
The Effect of Azithromycin on BCT197 Exposure in Healthy Male Volunteers
- First Posted Date
- 2016-10-06
- Last Posted Date
- 2016-10-24
- Lead Sponsor
- Mereo BioPharma
- Target Recruit Count
- 16
- Registration Number
- NCT02926326
- Locations
- 🇬🇧
BioKinetic Europe Ltd, Belfast, United Kingdom
A 6 Month Safety Extension Study of MBGS205
- First Posted Date
- 2016-09-20
- Last Posted Date
- 2023-05-18
- Lead Sponsor
- Mereo BioPharma
- Target Recruit Count
- 143
- Registration Number
- NCT02908074
- Locations
- 🇺🇸
Mereo Research Site, Kenosha, Wisconsin, United States
- Prev
- 1
- 2
- 3
- Next
News
Ultragenyx and Mereo BioPharma Advance Setrusumab Phase 3 Studies for Osteogenesis Imperfecta Toward Year-End Analysis
Ultragenyx and Mereo BioPharma announced that the Phase 3 Orbit study evaluating setrusumab (UX143) in pediatric and young adult patients with osteogenesis imperfecta is progressing toward final analysis around the end of 2025.
Mereo BioPharma's Setrusumab Shows Promise in Phase II, Alvelestat Gains EMA Orphan Status
Phase II results for setrusumab demonstrated significant improvements in fracture rates and bone strength, supporting continued development despite initial Phase III interim analysis outcomes.
Ultragenyx's Setrusumab Receives FDA Breakthrough Therapy Designation for Osteogenesis Imperfecta
• Ultragenyx's setrusumab (UX143) has been granted Breakthrough Therapy Designation by the FDA to reduce fracture risk in osteogenesis imperfecta (OI) patients. • The FDA's decision was based on positive data from the Phase 2 Orbit study and Phase 2b ASTEROID study, demonstrating a significant reduction in fracture rates. • Setrusumab, a fully human monoclonal antibody, inhibits sclerostin to enhance bone formation, density, and strength in OI patients. • The Breakthrough Therapy Designation aims to expedite the development and review of setrusumab, offering hope for an approved treatment option for OI.